- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07813689
Detection of Neurological Manifestations Among Neonates With Sepsis
Studieoversikt
Status
Detaljert beskrivelse
Neonatal sepsis remains a major global health problem and a leading cause of neonatal morbidity and mortality. Globally, an estimated 1.3-3.9 million cases occur annually, resulting in approximately 400,000-700,000 deaths each year. It is a life-threatening systemic inflammatory response to bacterial, viral, or fungal infections occurring during the first 28 days of life and may progress to multiorgan dysfunction and death.
Neonatal sepsis is classified into early-onset sepsis (EOS), occurring within the first 72 hours and usually related to vertical maternal transmission, and late-onset sepsis (LOS), occurring after 72 hours up to 28 days and commonly associated with postnatal or hospital-acquired infections.
Neonates are particularly susceptible to sepsis because of immature immune and barrier defenses. Neonatal polymorphonuclear leukocytes have impaired chemotaxis, adherence, and bactericidal activity. Humoral immunity depends largely on maternally derived IgG transferred during the last trimester, making preterm infants especially vulnerable due to reduced transplacental transfer. Immature skin and mucosal barriers further facilitate microbial invasion.
Sepsis results from a dysregulated systemic inflammatory response following failure to control the invading pathogen. Excessive release of cytokines such as IL-6 and TNF-α, together with vasoactive mediators including nitric oxide, prostaglandins, and leukotrienes, causes endothelial dysfunction, vasodilation, increased vascular permeability, hypotension, impaired tissue perfusion, and potentially multiorgan dysfunction.
The developing neonatal brain is particularly vulnerable to these systemic effects. Inflammatory and vasoactive mediators can disrupt the blood-brain barrier, while cerebral circulatory disturbances, endothelial injury, neurotransmitter dysregulation, and oxidative stress may contribute to central nervous system (CNS) injury. In addition, blood-brain barrier dysfunction may facilitate pathogen entry into the CNS, increasing the risk of meningitis and cerebral dysfunction. Systemic inflammation may also cause white matter injury through oligodendrocyte damage and impaired cerebral perfusion, particularly in preterm infants.
Neurological manifestations of neonatal sepsis may include altered consciousness, seizures, abnormal tone and reflexes, apnea, and feeding difficulties with risk of aspiration. Cohort studies, particularly in preterm infants, have also demonstrated an increased risk of adverse long-term neurodevelopmental outcomes following neonatal sepsis.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Amal AbdEltawab Hussein, Resident
- Telefonnummer: +201150832952
- E-post: amal.18313308@med.aun.edu.eg
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Neonates aged 0-28 days ( both fullterm and preterm neonates).
- Diagnosed with neonatal sepsis.
- Admitted to the NICU during the study period.
Exclusion Criteria:
- Neonates with major congenital anomalies of the central nervous system.
- Neonates with hypoxic-ischemic encephalopathy.
- Neonates with confirmed inborn errors of metabolism.
- Neonates with chromosomal abnormalities.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
The study will include neonates diagnosed with neonatal sepsis who are admitted to the NICU
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Detection of neurological manifestations among neonates with sepsis.
Tidsramme: baseline
|
baseline
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
- Types of neurological manifestations among neonates with sepsis.
Tidsramme: baseline
|
baseline
|
|
- Clinical charatericstics of septic neonates with and without neurological manifestations
Tidsramme: baseline
|
baseline
|
|
- laboratory characteristics of septic neonates with and without neurological manifestations
Tidsramme: baseline
|
baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Emad El-Deen Mahmoud Hammad El-daly, professor, pediatrics Department, Assiut University Hospitals
- Studieleder: Amira Mohamed Shalaby, assistant professor, pediatrics Department, Assiut University Hospitals
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Schlapbach LJ, Aebischer M, Adams M, Natalucci G, Bonhoeffer J, Latzin P, Nelle M, Bucher HU, Latal B; Swiss Neonatal Network and Follow-Up Group. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics. 2011 Aug;128(2):e348-57. doi: 10.1542/peds.2010-3338. Epub 2011 Jul 18.
- Hossain N, Rumman R, Alam MS, Jahan A, Mahmud R, Parajuli S, Shahidullah M, Mannan A. Detection of Neurological Complications by Cranial Ultrasound in Neonatal Sepsis: A Cross-sectional Study. J Pediatr Acad. 2024;5(4):116-122. doi:10.4274/jpea.2024.322.
- World Health Organization. Global report on the epidemiology and burden of neonatal sepsis. Geneva: World Health Organization; 2024.
- Kurul S, Beckers FLM, Vermeulen MJ, Suurland J, Hasbek JE, Ramakers CRB, Simons SHP, Reiss IKM, Taal HR. Inflammation, sepsis severity and neurodevelopmental outcomes of late-onset sepsis in preterm neonates. Pediatr Res. 2023 Dec;94(6):2026-2032. doi: 10.1038/s41390-023-02742-8. Epub 2023 Jul 19.
- Dumbuya JS, Li S, Liang L, Zeng Q. Paediatric sepsis-associated encephalopathy (SAE): a comprehensive review. Mol Med. 2023 Feb 23;29(1):27. doi: 10.1186/s10020-023-00621-w.
- Raturi A, Chandran S. Neonatal Sepsis: Aetiology, Pathophysiology, Diagnostic Advances and Management Strategies. Clin Med Insights Pediatr. 2024 Sep 25;18:11795565241281337. doi: 10.1177/11795565241281337. eCollection 2024.
- Kariniotaki C, Thomou C, Gkentzi D, Panteris E, Dimitriou G, Hatzidaki E. Neonatal Sepsis: A Comprehensive Review. Antibiotics (Basel). 2024 Dec 25;14(1):6. doi: 10.3390/antibiotics14010006.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Neurolgy -Nonates-Assiut-2026
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .